Therefore, exploring individual differences and epigenetic modifications in CD8 + TEX cells in HCC enables targeted intervention for personalized, comprehensive treatment, enhancing survival prognosis and developing more effective treatment methods. This evidence concerns the gene CD8A and hepatocellular carcinoma.